Real-World Tinnitus Data Underscore Clinical Performance of Neuromod’s Lenire Device

According to a recent LinkedIn post from Neuromod Devices Ltd, recent coverage by MassDevice discusses a second real-world analysis of U.S. tinnitus patients treated with the company’s Lenire device. The post notes that the paper, authored by Dr. Craig Kasper of NYHD | Institute for Hearing & Balance and published in ASHA Journals, reports that 81.8% of 140 patients experienced tinnitus relief and showed a mean reduction of 23.8 points on the Tinnitus Handicap Inventory scale.

The LinkedIn post further indicates that these outcomes are consistent with a prior real-world analysis of U.S. tinnitus patients treated with Lenire, which appeared in a Nature Portfolio publication. For investors, the convergence of independent clinical evaluations suggesting repeatable symptom relief may strengthen Neuromod Devices’ evidence base, potentially supporting payer discussions, clinician adoption, and the long-term commercial prospects of its FDA-approved tinnitus treatment platform in the audiology and hearing care markets.